Skip to main content

Advertisement

SpringerLink
Log in

The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives

  • Review - Gynecologic Oncology
  • Published:
Archives of Gynecology and Obstetrics Aims and scope Submit manuscript

Abstract

Purpose

Optimal first-line chemotherapy regimens are crucial for epithelial ovarian cancer (EOC) treatment. Nab-paclitaxel has showed its considerable survival and low toxicity profiles in first-line treatment for three solid tumors and is recommended as a treatment for recurrent EOC. We focus on clinical efficacy and safety outcomes of nab-paclitaxel in current clinical studies of EOC treatment and aim to explore the potential feasibility of nab-paclitaxel as the first-line treatment for EOC.

Methods

We searched for eligible studies up to January 2020 in Pubmed. Outcomes of interests included drug regimes, objective response rate (ORR), median progression free survival (PFS), median overall survival (OS) and main adverse events to determine feasibility of nab-paclitaxel.

Results

This review included nine eligible studies. One study about nab-paclitaxel with carboplatin as first-line therapy in ten cases after hypersensitivity to paclitaxel had an ORR of 100%, median PFS of 16.7 months and median OS of 65.4 months. Evidence of nab-paclitaxel activity in platinum-sensitive EOC demonstrated an ORR of 64%, a median time to response of 1.3 months and PFS of 8.5 months. The ORR, median PFS and median OS range in patients with recurrent platinum-resistant EOC from 23%–72%, 4.0–8.5 months, 16.8–17.4 months, respectively. All studies demonstrated manageable toxicity profile in EOC patients.

Conclusion

Nab-paclitaxel presents potentials as the first-line chemotherapy for considerable survival and safety in EOC compared to conventional paclitaxel. However, there is no prospective trial in EOC so far. Therefore, more studies about nab-paclitaxel are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Reid BM, Permuth JB, Sellers TA (2017) Epidemiology of ovarian cancer: a review. Cancer Biol Med 14(1):9–32

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Tsibulak I, Zeimet AG, Marth C (2019) Hopes and failures in front-line ovarian cancer therapy. Crit Rev Oncol Hematol 143:14–19

    Article  PubMed  Google Scholar 

  3. du Bois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M et al. (2005) 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Annals of oncology: official journal of the European Society for Medical Oncology, pp viii7–viii12.

  4. Vasey PA, Jayson GC, Gordon A, Gabra H, Coleman R, Atkinson R et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96(22):1682–1691

    Article  CAS  PubMed  Google Scholar 

  5. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92(9):699–708

    Article  CAS  PubMed  Google Scholar 

  6. Kampan NC, Madondo MT, McNally OM, Quinn M, Plebanski M (2015) Paclitaxel and its evolving role in the management of ovarian cancer. Biomed Res Int 2015:413076

    Article  PubMed  PubMed Central  Google Scholar 

  7. Taxotere Prescribing Information (2013). http://products.sanofi.us/taxotere/Taxotere.html. Accessed 24 Dec 2013

  8. Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E (1987) Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47(9):2486–2493

    CAS  PubMed  Google Scholar 

  9. Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL et al (1990) Hypersensitivity reactions from taxol. J Clin Oncol 8(7):1263–1268

    Article  CAS  PubMed  Google Scholar 

  10. van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K et al (2001) Pharmacokinetic modeling of paclitaxel encapsulation in cremophor EL micelles. Cancer Chemother Pharmacol 47(4):309–318

    Article  PubMed  Google Scholar 

  11. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A et al (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12(4):1317–1324

    Article  CAS  PubMed  Google Scholar 

  12. Kundranda MN, Niu J (2015) Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des Devel Ther 9:3767–3777

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132(3):171–183

    Article  CAS  PubMed  Google Scholar 

  14. Maeda H (2012) Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. J Control Release 164(2):138–144

    Article  CAS  PubMed  Google Scholar 

  15. Vogel SM, Minshall RD, Pilipovic M, Tiruppathi C, Malik AB (2001) Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol 281(6):L1512-1522

    Article  CAS  PubMed  Google Scholar 

  16. Desai N, Trieu V, Damascelli B, Soon-Shiong P (2009) SPARC expression correlates with tumor response to albumin-bound paclitaxel in head and neck cancer patients. Transl Oncol 2(2):59–64

    Article  PubMed  PubMed Central  Google Scholar 

  17. Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E et al (2002) Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 8(5):1038–1044

    CAS  PubMed  Google Scholar 

  18. Parisi A, Palluzzi E, Cortellini A, Sidoni T, Cocciolone V, Lanfiuti Baldi P et al (2020) First-line carboplatin/nab-paclitaxel in advanced ovarian cancer patients, after hypersensitivity reaction to solvent-based taxanes: a single-institution experience. Clin Transl Oncol 22(1):158–162

    Article  CAS  PubMed  Google Scholar 

  19. Teneriello MG, Tseng PC, Crozier M, Encarnacion C, Hancock K, Messing MJ et al (2009) Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 27(9):1426–1431

    Article  CAS  PubMed  Google Scholar 

  20. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS et al (2011) A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 122(1):111–115

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Tillmanns TD, Lowe MP, Walker MS, Stepanski EJ, Schwartzberg LS (2013) Phase II clinical trial of bevacizumab with albumin-bound paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. Gynecol Oncol 128(2):221–228

    Article  CAS  PubMed  Google Scholar 

  22. Liao JB, Swensen RE, Ovenell KJ, Hitchcock-Bernhardt KM, Reichow JL, Apodaca MC et al (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144(3):480–485

    Article  CAS  PubMed  Google Scholar 

  23. Gardner ER, Dahut WL, Scripture CD, Jones J, Aragon-Ching JB, Desai N et al (2008) Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 14(13):4200–4205

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V et al (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23(31):7785–7793

    Article  CAS  PubMed  Google Scholar 

  25. Cristea MC, Frankel P, Synold T, Rivkin S, Lim D, Chung V et al (2019) A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemother Pharmacol 83(3):589–598

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Cohen AL, Ray A, Van Brocklin M, Burnett DM, Bowen RC, Dyess DL et al (2017) A phase I trial of azacitidine and nanoparticle albumin bound paclitaxel in patients with advanced or metastatic solid tumors. Oncotarget 8(32):52413–52419

    Article  PubMed  Google Scholar 

  27. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803

    Article  CAS  PubMed  Google Scholar 

  28. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30(17):2055–2062

    Article  CAS  PubMed  Google Scholar 

  29. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M et al (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703

    Article  Google Scholar 

  30. Szebeni J, Muggia FM, Alving CR (1998) Complement activation by cremophor EL as a possible contributor to hypersensitivity to paclitaxel: an in vitro study. J Natl Cancer Inst 90(4):300–306

    Article  CAS  PubMed  Google Scholar 

  31. Essayan D, Kagey-Sobotka A, Colarusso P, Lichtenstein L, Ozols R, King E (1996) Successful parenteral desensitization to paclitaxel. J Allergy Clin Immunol 97:42–46

    Article  CAS  PubMed  Google Scholar 

  32. Prieto García A, Pineda de la Losa F (2010) Immunoglobulin E-mediated severe anaphylaxis to paclitaxel. J Investig Allergol Clin Immunol 20(2):170–171

    PubMed  Google Scholar 

  33. Madrigal-Burgaleta R, Berges-Gimeno M, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C et al (2013) Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 68(7):853–861

    Article  CAS  PubMed  Google Scholar 

  34. Limsuwan T, Castells MC (2010) Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert Opin Drug Saf 9(1):39–53

    Article  CAS  PubMed  Google Scholar 

  35. Lindemann K, Christensen RD, Vergote I, Stuart G, Izquierdo MA, Kærn J et al (2012) First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG. Ann Oncol 23(10):2613–2619

    Article  CAS  PubMed  Google Scholar 

  36. Pignata S, Scambia G, Ferrandina G, Savarese A, Sorio R, Breda E et al (2011) Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol 29(27):3628–3635

    Article  CAS  PubMed  Google Scholar 

  37. Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374(9698):1331–1338

    Article  CAS  PubMed  Google Scholar 

  38. Pfisterer J, Weber B, Reuss A, Kimmig R, du Bois A, Wagner U et al (2006) Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst 98(15):1036–1045

    Article  CAS  PubMed  Google Scholar 

  39. Chan JK, Brady MF, Penson RT, Huang H, Birrer MJ, Walker JL et al (2016) Weekly vs every-3-week paclitaxel and carboplatin for ovarian cancer. N Engl J Med 374(8):738–748

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S et al (2014) Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 15(4):396–405

    Article  CAS  PubMed  Google Scholar 

  41. Gore M, Hackshaw A, Brady WE, Penson RT, Zaino R, McCluggage WG et al (2019) An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. Gynecol Oncol 153(3):541–548

    Article  PubMed  PubMed Central  Google Scholar 

  42. Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL et al (2017) Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 18(6):779–791

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Sugiyama T, Okamoto A, Enomoto T, Hamano T, Aotani E, Terao Y et al (2016) Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017/GCIG trial. J Clin Oncol 34(24):2881–2887

    Article  CAS  PubMed  Google Scholar 

  44. du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N et al (2016) Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 17(1):78–89

    Article  CAS  PubMed  Google Scholar 

  45. Hainsworth JD, Thompson DS, Bismayer JA, Gian VG, Merritt WM, Whorf RC et al (2015) Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute. Cancer Med 4(5):673–681

    Article  CAS  PubMed  Google Scholar 

  46. Pierce SR, Clark LH (2018) Current first-line therapy for ovarian cancer: a comprehensive review. Obstet Gynecol Surv 73(11):650–657

    Article  PubMed  Google Scholar 

  47. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37(13):1590–1598

    Article  CAS  PubMed  Google Scholar 

  48. Authier N, Gillet JP, Fialip J, Eschalier A, Coudore F (2001) Assessment of neurotoxicity following repeated cremophor/ethanol injections in rats. Neurotox Res 3(3):301–306

    Article  CAS  PubMed  Google Scholar 

  49. Yang E, Kang HJ, Koh KH, Rhee H, Kim NK, Kim H (2007) Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 121(3):567–575

    Article  CAS  PubMed  Google Scholar 

  50. Gadducci A, Cosio S, Conte PF, Genazzani AR (2005) Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature. Crit Rev Oncol Hematol 55(2):153–166

    Article  PubMed  Google Scholar 

  51. Volpe J, Filipi JG, Cooper OR, Penson RT (2018) Frontline therapy of ovarian cancer: trials and tribulations. Curr Opin Obstet Gynecol 30(1):1–6

    Article  PubMed  Google Scholar 

  52. Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H et al (2020) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(1):44–59

    Article  CAS  PubMed  Google Scholar 

  53. González-Martín A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza M et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381(25):2391–2402

    Article  PubMed  Google Scholar 

  54. Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M et al (2018) Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379(26):2495–2505

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

Beijing Xisike Clinical Oncology Research Founding Y-HR2019-0189 and Y-SY201901-0117.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Second Xiangya Hospital, Central South University, 139 Middle Renmin Road, Changsha, Hunan, 410011, People’s Republic of China

    Xue Yang & Chun Fu

Authors
  1. Xue Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chun Fu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

YX: protocol development, data collection, manuscript writing/editing. FC: protocol development, manuscript writing/editing.

Corresponding author

Correspondence to Chun Fu.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical statement

This study was approved by the Ethics Committee of Second Xiangya Hospital.

Informed consent statement

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (TIF 802 KB)

Supplementary file2 (TIF 966 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, X., Fu, C. The potential feasibility of nab-paclitaxel as the first-line chemotherapy for ovarian cancer: clinical development and future perspectives. Arch Gynecol Obstet 306, 1417–1429 (2022). https://doi.org/10.1007/s00404-022-06425-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00404-022-06425-3

Keywords

Search

Navigation